Evidence map›Paper›PMID 40593607›Full record

ArticleNature communications2025

A multicenter longitudinal study of cholinergic subgroups in Parkinson disease.

Nicolaas I Bohnen, Stiven Roytman, Sygrid van der Zee, Giulia Carli, Fotini Michalakis, Austin Luker, Sofie Slingerland, Kirk A Frey, Peter J H Scott, Robert A Koeppe and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Neuroprotection of engineeredJournal of Zhejiang University. Science. B · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Pharmacogenetics in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nicolaas I Bohnen *Department of Radiology, University of Michigan, Ann Arbor, MI, USA. nbohnen@umich.edu.ORCID http://orcid.org/0000-0003-0352-6414
Stiven Roytman *Department of Radiology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0001-8823-3287
Sygrid van der ZeeUniversity Medical Center Groningen, Department of Neurology, University of Groningen, Groningen, the Netherlands.
Giulia CarliMorris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI, USA.
Fotini MichalakisDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0009-0006-0836-445X
Austin LukerDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0009-0001-4408-2605
Sofie SlingerlandUniversity Medical Center Groningen, Department of Neurology, University of Groningen, Groningen, the Netherlands.
Kirk A FreyDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Peter J H ScottDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Robert A KoeppeDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Teus van LaarUniversity Medical Center Groningen, Department of Neurology, University of Groningen, Groningen, the Netherlands.
Roger L AlbinMorris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI, USA.
Prabesh KanelDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-1418-2960

Funding

Udall Catalyst Research Project: Retrosplenial Cholinergic and Attentional-Motor Integration DysfunctionP50NS123067 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI AHMED, OMAR JAMIL · 2021 to 2025
$11.6M
Public Outreach and Education CoreP50NS091856 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAUER, WILLIAM T. · 2014 to 2019
$10.1M
Central cholinergic presbyvestibulopathy network changes and imbalance in Parkinson's disease and older personsR01AG073100 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BOHNEN, NICOLAAS IDA · 2021 to 2025
$3.0M
NIA NIH HHS R01 AG073100NINDS NIH HHS P50 NS091856NINDS NIH HHS P50 NS123067RRD VA I01 RX001631RRD VA I01 RX003397
6 · The paper itself

Abstract

Parkinson disease (PD) is a heterogeneous syndrome. There is a need for biology-driven subtyping to inform specific therapeutic strategies. In a two-center study with de novo and established PD cohorts, we use vesicular acetylcholine transporter ligand [

Indexed as

AcetylcholineBrainParkinson DiseaseAgedDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedPositron-Emission TomographyPrincipal Component AnalysisVesicular Acetylcholine Transport ProteinsAcetylcholineVesicular Acetylcholine Transport Proteins

Identifiers

PMID40593607
PMCPMC12219741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.